Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

被引：0
|
作者：
Santini, Valeria [1 ]
Amato, Cristina [1 ]
De Pourcq, Sven [2 ]
della Seta, Roberta [3 ]
Caciagli, Barbara [1 ]
Raddi, Marco Gabriele [1 ]
Consagra, Angela [1 ]
Rigodanza, Luca [1 ]
Mattiuz, Giorgio [2 ]
Defina, Marzia [4 ]
Galimberti, Sara [5 ]
Maestrini, Giacomo [6 ]
Sanna, Alessandro [7 ]
机构：
[1] Univ Florence, MDS Unit, DMSC, AOU Careggi, Florence, Italy
[2] Univ Florence, MDS Unit, DMSC, Florence, Italy
[3] Azienda Osped Toscana Nord Ovest, Hematol, Massa Carrara, Italy
[4] Azienda Osped Univ Senese, Hematol, Siena, Italy
[5] Univ Pisa, Dept Clin & Expt Med, Hematol, Pisa, Italy
[6] AOU Toscana Ctr, Hematol, Florence, Italy
[7] AOU Careggi, Hematol, Florence, Italy
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-190016
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Azacitidine in the management of patients with myelodysplastic syndromes
    Khan, Cyrus
    Pathe, Neeta
    Fazal, Salman
    Lister, John
    Rossetti, James M.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (06) : 355 - 373
  • [32] An update on treatment of higher risk myelodysplastic syndromes
    Rahme, Ramy
    Ades, Lionel
    EXPERT REVIEW OF HEMATOLOGY, 2019, 12 (01) : 61 - 70
  • [33] Phase II Study of Oral Rigosertib Combined With Azacitidine as First-Line Therapy in Patients With Higher-Risk Myelodysplastic Syndromes
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02)
  • [34] A Phase II Study Of The Combination Of Azacitidine and Lenalidomide In Patients (pts) With Higher Risk Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Daver, Naval
    Jabbour, Elias
    Jain, Nitin
    Cortes, Jorge E.
    Estrov, Zeev
    Borthakur, Gautam
    Dong, Xiao Q.
    Kumar, Veeral J.
    Kantarjian, Hagop M.
    BLOOD, 2013, 122 (21)
  • [35] Azacitidine in lower-risk myelodysplastic syndromes
    Santini, Valeria
    LEUKEMIA RESEARCH, 2009, 33 : S22 - S26
  • [36] IMPACT OF AZACITIDINE TREATMENT ON INFECTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROMES AND MYELODYSPLASTIC/MYELOPROLIFERATIVE SYNDROMES
    Villegas, C.
    Ortiz, S.
    Javier, K.
    Costa, S.
    Ivars, D.
    Collado, R.
    Lopez, M.
    Irene, L.
    Roig, M.
    Sanchez, M.
    Perez, P.
    Orero, M.
    HAEMATOLOGICA, 2016, 101 : 483 - 483
  • [37] Management of patients with higher risk myelodysplastic syndromes
    Fukumoto, JS
    Greenberg, PL
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2005, 56 (02) : 179 - 192
  • [38] AZACITIDINE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE ANALYSIS
    Mousinho, F.
    Sousa e Santos, P.
    Viegas, E.
    Madureira, B.
    Gomes, A. P.
    Falcao, F.
    Lima, F.
    LEUKEMIA RESEARCH, 2017, 55 : S74 - S74
  • [39] Azacitidine - In myelodysplastic syndromes
    Siddiqui, MAA
    Scott, LJ
    DRUGS, 2005, 65 (13) : 1781 - 1789
  • [40] Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
    Fenaux, Pierre
    Bowen, David
    Gattermann, Norbert
    Hellstrom-Lindberg, Eva
    Hofmann, Wolf-Karsten
    Pfeilstoecker, Michael
    Sanz, Guillermo
    Santini, Valeria
    LEUKEMIA RESEARCH, 2010, 34 (11) : 1410 - 1416
12345